Type 2 inflammatory disorders

Clinical trials for Type 2 inflammatory disorders explained in plain language.

Never miss a new study

Get alerted when new Type 2 inflammatory disorders trials appear

Sign up with your email to follow new studies for Type 2 inflammatory disorders, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Last-Resort access to dupilumab for patients with severe inflammation

Disease control Expanded access

This program provides compassionate use of dupilumab (Dupixent) for patients with severe type 2 inflammatory disorders who have no other treatment options. It aims to offer access to this drug outside of a clinical trial. The program is already approved for marketing.

Matched conditions: TYPE 2 INFLAMMATORY DISORDERS

Sponsor: Regeneron Pharmaceuticals • Aim: Disease control

Last updated Sep 03, 2026 00:00 UTC

Type 2 inflammatory disorders

Get alerted when new Type 2 inflammatory disorders trials appear

Last-Resort access to dupilumab for patients with severe inflammation